EDadmin@hermes.cam.ac.uk
01223 763384
Members Area
Members Area
EDadmin@hermes.cam.ac.uk
01223 763384
Members Area
Members Area
Published: 04th September, 2018
Cancer Research UK have published their Annual Review for 2017/18 with a major focus on the Early Detection of Cancer. Pages 30-39 feature the chapter "Detecting and Diagnosing Cancer" which includes an article on Owlstone Medical and the PAN Cancer Trial that the company is running with the CRUK Cambridge Centre Early Detection Programme to detect cancer in breath samples.
The document also includes an interview with Sir Harpal Kumar, who stepped down as Chief Executive after more than 15 years with the charity. In his future vision he comments: “I hope it will include something in the area of early detection. We’re getting towards a breakthrough that’ll allow us to detect cancers at an early stage – including some of the most aggressive, dangerous ones – and that’s going to have a huge impact on survival.”
Please click here to open the report.
Published: 29th August, 2018
From September 2018 Cancer Research UK is removing the post-PhD time restrictions on applications for response-mode fellowships to ensure greater flexibility and equality.
Published: 22nd August, 2018
Trial aims to identify breath biomarkers to improve the early detection and diagnosis of different cancer types.
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, will run the PAN Cancer trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of Owlstone Medical’s Breath Biopsy® platform for the early detection of multiple cancer types.
Published: 01st August, 2018
New study reveals that it is possible to identify people at high risk of developing Acute Myeloid Leukaemia (AML) years before they became ill.
Published: 30th July, 2018
Successful application to Rosetrees Trust Interdisciplinary Prize 2018 for non-invasive diagnostic test for renal cell cancers at point of care.
Published: 16th July, 2018
The International Cell Senescence Association (ICSA) conference 2018 took place from July 8th-11th in Montreal, Canada and was attended by members of the Munoz-Espin lab. Estela Gonzalez-Gualda, PhD student in the lab, was awarded a poster prize at the conference. Many congratulations Estela.
Published: 03rd July, 2018
Mr Vincent Gnanapragasam and Professor Andrew Flewitt featured on the BBC Look East Evening News of 2 July 2018. They have both been working on new devices to improve accuracy in prostate cancer detection. The coverage shows both tools, the CamProbe and the FBAR which should be safer and more accurate than the current PSA test.
Published: 06th June, 2018
Sorex Sensors, a spin-out from the University of Cambridge Department of Engineering has secured an initial round of investment from Cambridge Enterprise, Cambridge Angels and Cambridge Capital Group. The Film Bulk Acoustic Resonator (FBAR) technology has many applications including in cancer detection. One of these applications in prostate cancer detection was investigated by Professor Flewitt and his team with funding from a CRUK Cambridge Centre Early Detection Programme pump-priming award.
Published: 22nd May, 2018
In a speech by Teresa May the Government has pledged millions of pounds of funding to develop artificial intelligence able to transform outcomes through early diagnosis of cancer and chronic disease through the Industrial Strategy Grand Challenges.
Industry and charities will work with the NHS to develop algorithms that can use patient data and lifestyle information to warn GPs when a patient should be referred to an oncologist or another specialist. It is estimated that AI could help prevent 22,000 deaths from cancer each year by 2033, and give patients an additional five years of healthy, independent life by 2035.
Published: 21st May, 2018
Dr Stephen John, Senior Lecturer in Philosophy of Public Health, Cambridge University has written about the ethical issues surrounding the recent news that IT errors resulted in women not being invited to their final breast screening appointment. He asks: 'Was anyone harmed by the breast cancer screening scandal?' In this balanced analysis Stephen argues that it all depends which direction you look in - read here